Mycosyst, 150 mg capsules 2 pcs

Mycosyst is an antifungal drug. Fluconazole, a representative of the class of triazole antifungal agents, is a selective inhibitor of sterol synthesis in the fungal cell.

Fluconazole, being highly selective for cytochrome P450 of fungi, practically does not inhibit the system of cytochrome P450 in humans (compared to itraconazole, clotrimazole, econazole and ketoconazole it inhibits cytochrome P450 dependent oxidation processes in human liver microsomes to a lesser extent).

It has no androgenic activity.

It is active against mycosis pathogens caused by Candida spp., Cryptococcus neoformans, Microsporum spp., Trichophyton spp. Fluconazole activity has also been shown in models of endemic mycoses, including infections caused by Blastomyces dermatitidis, Coccidioides immitis and Histoplasma capsulatum.

Pharmacokinetics

Absorption

Fluconazole is well absorbed after oral administration, its bioavailability is 90%. Cmax after oral administration on an empty stomach of 150 mg is reached after 0.5-1.5 hours and makes 90% of concentrations in plasma in a dose of 2.5-3.5 mg/kg. Concomitant intake of food has no effect on absorption of the drug taken orally.

Distribution

Fluconazole penetrates well into all tissues and body fluids after oral and intravenous administration. High concentrations are achieved in the stratum corneum, dermis and sweat fluids, which exceed serum concentrations. After oral administration of 150 mg on day 7, the concentration in the stratum corneum of the skin is 23.4 mcg/g, and 1 week after the second dose – 7.1 mcg/kg, the concentration in the nails after 4 months of use at a dose of 150 mg once/week is 4.05 mcg/g in healthy and 1.8 mcg/g in the affected nails.

The drug concentrations in saliva, sputum, breast milk, joint and peritoneal fluid are similar to its plasma concentrations. In patients with fungal meningitis, fluconazole content in cerebrospinal fluid reaches 80% of the corresponding concentration in plasma. Constant values in vaginal secretion are reached 8 hours after oral administration and remain at this value for at least 24 hours.

Plasma concentrations are directly proportional to the dose. 90% equilibrium concentrations are reached by day 4-5 when administered daily by oral or intravenous injection once daily.

The first day’s dose of twice the usual daily dose achieves 90% of the equilibrium concentration by the second day. The apparent Vd approaches the total volume of water in the body. With plasma proteins 11-12% of fluconazole is bound.

Metabolism and excretion

It is an inhibitor of CYP2C9 isoenzyme in the liver. No fluconazole metabolites were detected in the peripheral blood.

T1/2 – 30 h. Fluconazole pharmacokinetics depends significantly on the functional state of the kidneys, and there is an inverse relationship between T1/2 and creatinine clearance. Fluconazole is excreted mainly by the kidneys; approximately 80% of the administered dose is excreted unchanged. Fluconazole clearance is directly proportional to creatinine clearance.

In 3 hours after hemodialysis plasma concentration of fluconazole decreases by 50%.

Indications

Skin fungus, Fungus, thrush (candida), Nail fungus, Itching and dryness in the genital area, Skin itching

• fungus of the skin, nails and internal organs
• candidosis of mucous membranes
• antifungal cover during antibiotic treatment.

.

Active ingredient

Fluconazole

Composition

1 capsule contains:

Active substance:

fluconazole150 mg;

Associates:

colloidal silica;

magnesium stearate;

p> talc;

povidone;

corn starch;

anhydrous lactose.

How to take, the dosage

Use in adults

In cryptococcal infections the usual dose of fluconazole is 400 mg once daily on the first day of treatment, thereafter 200-400 mg once daily. The duration of treatment in cryptococcal infections depends on the clinical efficacy confirmed by mycological study, and usually is from 6 to 8 weeks.

The recommended duration of treatment for therapy of cryptococcal meningitis is 10-12 weeks after a negative result of microbiological examination of the cerebrospinal fluid sample.

In order to prevent relapse of cryptococcal meningitis in AIDS patients after completion of complete primary therapy, fluconazole is given at a minimum dose of 200 mg daily for an extended period.

In candidemia, disseminated candidiasis and other invasive candidiasis infections, the daily dose of fluconazole is 400 mg on the first day and 200 mg on subsequent days. If necessary, the drug dose may be increased to 400 mg/day. The duration of treatment depends on clinical efficacy.

In severe systemic candidiasis it is possible to increase the dose to 800 mg/day. Duration of therapy depends on clinical efficacy. It should be continued for at least 2 weeks after obtaining of negative hemoculture or after disappearance of disease symptoms.

In oropharyngeal candidiasis, including patients with immune disorders, the usual dose of fluconazole is 50-100 mg/day for 7-14 days. For prophylaxis of oropharyngeal candidiasis relapses in AIDS patients after full course of primary therapy, 150 mg once a week. If necessary, treatment may be prolonged, especially in case of severe immune disorders.

In atrophic oral candidiasis associated with the wearing of dentures, fluconazole is usually prescribed 50 mg/day for 14 days in combination with antiseptics for denture treatment.

In other candida infections such as esophagitis, non-invasive bronchopulmonary infections, candidiasis, candidiasis of the skin and mucous membranes, the daily dose is 50-100 mg for 14-30 days.

In severe candidiasis of mucous membranes 100-200 mg/day.

For prevention of fungal infections in patients with malignancies, the dose of fluconazole should be 50 mg/day as long as the patient is at high risk due to cytostatic or radiation therapy.

In case of vaginal candidiasis, 150 mg once. To reduce the recurrence rate, use 150 mg once a month for 4-12 months, sometimes more frequent use may be necessary.

For balanitis caused by Candida spp., fluconazole is prescribed once in a dose of 150 mg orally (capsules).

For the prevention of candidiasis, the recommended dose of fluconazole is 50-400 mg/day depending on the degree of risk of fungal infection. If there is a high risk of generalized infection, such as in patients with expected severe or prolonged neutropenia, the recommended dose is 400 mg/day. Fluconazole is administered several days before the expected appearance of neutropenia; after neutrophil count increases more than 1000/mm3, the treatment is continued for another 7 days.

In mycoses of the skin (including candidiasis), including mycoses of the feet, skin, and groin, the recommended dose is 150 mg once weekly or 50 mg/day. Duration of therapy in common cases is 2-4 weeks, but in case of mycoses of feet a longer therapy of up to 6 weeks may be required (capsules).

In pityriasis, 300 mg once weekly for 2 weeks; some patients require a third dose of 300 mg/week, but in some cases a single dose of 300 mg is sufficient; an alternative regimen is 50 mg/day for 2-4 weeks (capsules).

In onychomycosis, the recommended dose is 150 mg once weekly. Treatment should be continued until the infected nail is replaced by a healthy nail. It normally takes 3-6 and 6-12 months respectively for re-growth of nails on fingers and feet (capsules).

In deep endemic mycoses, it may be necessary to use the drug at a dose of 200-400 mg/day for 2 years. The duration of therapy is determined individually; it can be 11-24 months in coccidioidosis; 2-17 months in paracoccidioidosis and 3-17 months in histoplasmosis.

Performance in children

The duration of treatment depends on the clinical and mycological effect. In children, the drug should not be used in a daily dose higher than that of adults. Fluconazole is used daily once a day.

In mucosal candidiasis, the recommended dose of fluconazole is 3 mg/kg/day. A shock dose of 6 mg/kg may be administered on the first day in order to achieve Css more rapidly.

For the treatment of generalized candidiasis and cryptococcal infection, the recommended dose is 6-12 mg/kg/day depending on the severity of the disease.

For the prevention of fungal infections in immunocompromised children whose risk of infection is associated with neutropenia resulting from cytotoxic chemotherapy or radiation therapy, the drug is indicated at 3-12 mg/kg/day, depending on the severity and duration of the induced neutropenia.

Perhaps in older patients

In the absence of renal dysfunction, the usual recommendations for dosing of the drug should be followed. For patients with impaired renal function (creatinine Cl

Use in patients with renal impairment

Fluconazole is mainly excreted unchanged by the kidneys. There is no need to change the dose when using fluconazole alone. In patients (including children) with impaired renal function, a shock dose of 50 to 400 mg should be administered initially. Subsequently daily dose (depending on indication) is determined by the following methodology: in creatinine Cl >50 ml/min – 100% of the recommended dose once daily; in creatinine Cl

.

Interaction

Anticoagulants. In patients taking fluconazole and indirect coumarin anticoagulants, close monitoring of PV is necessary, because it may increase.

Sulfonylurea drugs. Fluconazole concomitantly administered may prolong T1/2 of sulfonylurea derivatives, therefore the possibility of hypoglycemia should be considered when using them together.

Phenytoin. Concomitant use of fluconazole and phenytoin may be accompanied by clinically significant increase in phenytoin concentration, which requires reducing its dose.

Rifampicin. Concomitant administration of Rifampicin and fluconazole decreases Cmax and T1/2 of the latter, therefore the fluconazole dose should be increased if co-administration is necessary.

Rifabutin. Concomitant use of fluconazole and rifabutin is accompanied by increased serum concentrations of the latter, and uveitis may occur.

Cyclosporine. When co-administration of fluconazole and cyclosporine it is recommended to monitor the concentration of the latter in blood, because it may increase.

Terfenadine. Because of the occurrence of serious, life-threatening arrhythmias in patients taking antifungal agents – azole derivatives in combination with terfenadine, their combined use is contraindicated.

Cisapride. In concomitant use of fluconazole and cisapride there have been described the cases of adverse reactions of the heart, including paroxysms of ventricular tachycardia. Simultaneous use is contraindicated.

Zidovudine. When combined with fluconazole, an increase in plasma concentrations of zidovudine is possible. Patients taking this combination should be monitored to detect side effects of zidovudine.

Theophylline. Administration of fluconazole leads to decreased average blood plasma clearance rate of theophylline; consequently, the risk of development of toxic effects of theophylline and its overdose increases.

Midazolam. Concomitant use of fluconazole and midazolam leads to a significant increase in plasma concentrations of the latter and risk of psychomotor reactions.

Hydrochlorothiazide. Concomitant administration of fluconazole and hydrochlorothiazide increases plasma concentrations of fluconazole by 40%.

Tacrolimus. Concomitant administration of fluconazole and tacrolimus increases the concentration of the latter in blood serum, which leads to an increased risk of nephrotoxicity.

We should use fluconazole with caution in patients receiving other drugs metabolized by cytochrome P450 system concomitantly.

.

Special Instructions

Treatment with fluconazole should be continued until clinical and hematological remission occurs. Premature discontinuation of treatment leads to relapses.

As fluconazole is mainly excreted by the kidneys, caution should be exercised in patients with renal insufficiency. During long-term treatment with fluconazole, dosing should be adjusted for creatinine clearance. In rare cases the use of fluconazole was accompanied by toxic effects on the liver, including with fatal outcome, mainly in patients with serious comorbidities. It is necessary to monitor the liver function. If there are signs of liver damage, which may be associated with fluconazole administration, the drug should be stopped.

A rare cases of exfoliative skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in patients while taking the drug. Patients with AIDS and malignancies are more prone to develop severe skin reactions when using many drugs.

If a patient develops a superficial fungal infection rash during treatment that can be associated with fluconazole use, the drug should be discontinued. Patients with invasive/systemic fungal infections should be closely monitored and fluconazole should be discontinued if bullous lesions or erythema multiforme appear. Caution should be exercised when concomitant administration of fluconazole with rifabutin or other drugs metabolized by cytochrome P450 system.

PH should be monitored in patients receiving fluconazole and coumarin-type indirect anticoagulants concomitantly.

Impact on the ability to drive and operate other mechanical equipment.Patients should exercise caution when driving motor vehicles or operating machinery, because dizziness may occur during treatment with fluconazole.

.

Contraindications

• concurrent use of terfenadine (with continued use of fluconazole at a dose of 400 mg/day or more) and cisapride, because both drugs prolong the QT interval and increase the risk of severe cardiac arrhythmias Both agents prolong the QT interval and increase the risk of
• current use of astemizole
• lactation (breastfeeding)
• lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
• high sensitivity to the drug components or similar azole compounds.

With caution: hepatic and/or renal insufficiency; occurrence of rash on fluconazole in patients with superficial fungal infection and invasive/systemic fungal infections; simultaneous administration of fluconazole with rifabutin or other drugs metabolized by cytochrome P450 system isoenzymes; concomitant use of terfenadine and fluconazole in dose less than 400 mg/day; potentially proarrhythmogenic conditions in patients with multiple risk factors (organic heart disease, electrolyte imbalance, concomitant use of drugs that cause arrhythmias); intolerance of acetylsalicylic acid; pregnancy.

.

Side effects

Digestive system disorders: nausea, vomiting, diarrhea, flatulence, abdominal pain, change in taste, liver function disorders (hyperbilirubinemia, increased liver transaminases activity, alkaline phosphatase, jaundice, hepatitis, hepatocellular necrosis, including fatal).

Nervous system disorders: headache, dizziness, seizures.

Hematopoietic disorders: leukopenia, thrombocytopenia, neutropenia, agranulocytosis.

Allergic reactions: skin rash, erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome), anaphylactoid reactions (including angioedema).angioneurotic edema, facial edema, urticaria, skin itching), bronchial asthma (often with intolerance to acetylsalicylic acid).

Systemic diseases: prolongation of QT interval on ECG, ventricular fibrillation/tripping.

Others: impaired renal function, alopecia, hypercholesterolemia, hypertriglyceridemia, hypokalemia.

.

Overdose

Symptoms: nausea, vomiting, diarrhea; in severe cases seizures, hallucinations, paranoid behavior may be noted.

Treatment: symptomatic (gastric lavage, forced diuresis, hemodialysis). After a 3-hour session of hemodialysis the plasma concentration of fluconazole decreases by approximately 50%.

.

Pregnancy use

The use of fluconazole during pregnancy is possible only when the potential benefit to the mother outweighs the risk to the fetus.

Fluconazole is detected in breast milk at the same concentration as in plasma, so its administration during lactation is contraindicated.

.

Similarities

Diflucan, Flucostat, Mycosist, Mycomax, Fluconazole-Teva, Fluconazole, Fluconazole Stada, Fluconazole Sandoz